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Purpose: To examine the efficacy of rituximab as a monotherapy or in combination therapy 
for the treatment of patients with non-paraneoplastic autoimmune retinopathy.
Methods: Twelve eyes of six patients with non-paraneoplastic autoimmune retinopathy who 
were treated with rituximab and had at least 6 months of follow-up were included. Demographic 
data, clinical data, visual field parameters, electroretinography parameters, and anti-retinal and 
anti-optic nerve autoantibody bands were collected from the Massachusetts Eye Research and 
Surgery Institution database between September 2010 and January 2015. Changes in visual 
acuity, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic 
nerve autoantibody bands from the initial visit to the most recent visit were examined.
Results: From the initial visit to the last visit, visual acuity was stable in eight (66.7%) eyes. 
Visual field was stable in six (50%) eyes and improved in two (16.7%) eyes. Electroretinography 
was stable or improved in eight (66.7%) eyes. The average number of anti-retinal and anti-optic 
nerve antibody bands was reduced.
Conclusion: Stabilization and/or improvement of visual acuity, visual field parameters, and 
electroretinography parameters were observed in a high number of patients (75%) on rituximab, 
as a monotherapy (one patient) or in combination therapy.
Keywords: birdshot retinochoroidopathy, bortezomib, CD20, cyclophosphamide, HLA-A29, 
HLA-B27, immunomodulatory therapy, systemic lupus erythematosus
Introduction
Autoimmune retinopathy (AIR) is an immune-mediated retinopathy that can cause 
acute, subacute and chronic vision loss, visual field defects, photopsias, nyctalopia, and 
color vision defects.1,2 AIR is characterized by the presence of circulating anti-retinal 
antibodies that are believed to damage photoreceptors in the retina; however, the exact 
mechanism is not entirely understood.3,4
AIR is subdivided into paraneoplastic (cancer-associated retinopathy and melanoma-
associated retinopathy) and non-paraneoplastic categories. Non-paraneoplastic 
AIR is composed of a large group of autoimmune retinopathies with features similar 
to those of carcinoma-associated retinopathy, but without any known underlying 
malignancy. Non-paraneoplastic AIR is usually diagnosed at a younger age,4 in people 
with a known personal and/or familial history of autoimmune diseases.2,5,6
Long-term immunosuppressive therapy is considered the mainstay of treatment 
for AIR.7 Different regimens of immunomodulatory therapy, such as corticosteroid,8 
plasmaphoresis,9 intravenous immunoglobulin,10 cyclosporine,6 and mycophenolate 
mofetil,6 have been used in the treatment of paraneoplastic and non-paraneoplastic AIR. 
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However, the rarity of this entity combined with difficulty 
in confirming the diagnosis and monitoring the response 
to treatment makes treatment challenging.5 Rituximab, a 
cluster of differentiation 20 molecule inhibitor (CD20), has 
been used as a treatment option for carcinoma-associated 
retinopathy in limited studies.11,12 There is also a case report 
using rituximab in the treatment of non-paraneoplastic AIR.13 
The aim of this study is to examine the efficacy of rituximab 
as a monotherapy or in combination therapy in preserving 
or improving visual function parameters in patients with 
non-paraneoplastic AIR.
Methods
This was a single-center, retrospective interventional case 
series of patients with non-paraneoplastic AIR who were 
treated at the Massachusetts Eye Research and Surgery Insti-
tution (MERSI) between September 2010 and January 2015. 
Each patient had at least 6 months of follow-up from when 
the diagnosis of non-paraneoplastic AIR was made. Ethical 
approval for this study was obtained through the New England 
Institutional Review Board, which issued a waiver of written 
informed consent based on standard operating procedures 
for retrospective chart reviews. This study was performed in 
accordance with the Declaration of Helsinki and was Health 
Insurance Portability and Accountability Act compliant.
Diagnosis of AIR was made based on four essential 
criteria with subjective symptoms as supportive criteria.5 
Essential criteria included no evidence of systemic mali-
gnancies or infections after a complete history was taken 
and a physical examination and appropriate testing were 
performed; no evidence of a preexisting degenerative eye 
disease; confirmed progressive abnormality on repeated 
electroretinography and/or visual field; and the presence of 
anti-retinal and/or anti-optic nerve antibodies. Supportive 
criteria were the acute or subacute presence of symptoms, 
such as decreased vision, visual field defects, nyctalopia, 
photoaversion, photopsia, and color vision deficits in patients 
without active anterior or posterior uveitis.
Blood samples and pertinent medical history of each 
patient were collected at MERSI and were sent to the com-
mercially available testing center at Oregon Health Sciences 
University. Western blots were used to evaluate the presence 
of the anti-retinal and anti-optic nerve antibodies. These tests 
were repeated every 6 months.
All patients underwent fluorescein angiography, indo-
cyanine green (ICG) angiography, full-field electroretinogra-
phy, and automated perimetry. Optical coherence tomography 
was obtained as part of the initial examination or follow-up 
examinations in all patients with clinical evidence of decreased 
central visual acuity at any time or angiographic suspicion of 
macula edema.
Patient demographics, including personal and family 
histories of autoimmune diseases, were collected. Best 
corrected visual acuity and related logarithm of the minimum 
angle of resolution (LogMAR) were recorded for every 
patient at the initial and most recent visits. Humphrey 
visual field (HVF; Carl Zeiss Meditec, Inc., Dublin, CA, 
USA) and Ganzfeld electroretinography (SG-2002, LKC 
Technologies, Gaithersburg, MD) were also performed on 
all patients at the initial and most recent visits. Anti-retinal 
and anti-optic nerve autoantibody bands, reported based on 
their molecular weights (kDa), were recorded at the initial and 
most recent visits. Furthermore, anti-retinal and anti-optic 
nerve antibodies were divided into pathologically proven 
and nonspecific groups, as based on the previous studies.2,5,14 
After a thorough analysis of the patient’s records, treatment 
regimens, the duration of each regimen, reported clinical 
and laboratory (blood and urine) side effects, and reasons for 
premature termination of a treatment regimen and its related 
date were recorded for every patient in the study.
Visual fields were analyzed with the Humphrey Visual 
Field Analyzer (Carl Zeiss Meditec, Inc.) under 24-2 
FASTPAC or Swedish Interactive Threshold Activity (SITA) 
fast strategy for all patients, except those with a previous 
diagnosis of birdshot retinochoroidopathy. Short-wavelength 
automated perimetry (SITA-SWAP) was used to evaluate 
the visual fields of patients with a previous diagnosis of 
birdshot retinochoroidopathy as it has been shown to be 
more accurate in these patients.15 Visual field parameters 
recorded were total deviation, pattern deviation, mean devia-
tion, and pattern standard deviation. The standardized visual 
field criteria of the Optic Neuritis Treatment Trial protocol 
were used to interpret visual field patterns.16,17 A field defect 
was defined as three or more significant (P,0.05) non-edge 
contiguous points, with at least one at the (P,0.01) level on 
the same side of the horizontal meridian.18,19 Ganzfeld elec-
troretinography (SG-2002, LKC Technologies) parameters 
included scotopic b-wave amplitude, maximal combined 
a-wave and b-wave amplitudes, 30-Hz flicker amplitude, 
and 30-Hz flicker implicit time. The percentage of each of 
these parameters to the mean normal control values were 
calculated for statistical analysis.
The treatment protocol for rituximab was 375 mg/m2 
every week for 8 weeks, then 375 mg/m2 monthly.20,21 Oral 
cyclophosphamide was used at a dose of 2 mg/kg/day. 
Bortezomib was the other medication, used at a dose of 
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1.3 mg/m2 through the subcutaneous route at days 1, 4, 8, 
and 11; this was repeated every 21 days. All patients were 
monitored closely for occult side effects of all medications 
via a complete review of systems at each visit and periodical 
blood tests, including blood cell counts, blood urea 
nitrogen, creatinine, and liver function tests. In patients 
on cyclophosphamide, urine samples were analyzed for 
hematuria every other month. The decision for rituximab 
monotherapy or in combination therapy was made based on 
the severity of the disease.
Severe disease was defined as visual acuity 20/200 or 
worse; or mean deviation worse than -12 dB, .50% of 
points depressed ,5% level and .25% depressed ,1% 
level on pattern deviation plot, any point within 5° of fixa-
tion 0 dB. Both hemifield contain point(s) ,15 dB within 
5° of fixation;22 or flat or near flat 30-Hz flicker amplitude 
and/or combined a-wave and b-wave amplitudes.
We looked for stability or improvement of visual acuity, 
HVF patterns and parameters (total deviation, pattern 
deviation, mean deviation, and pattern standard deviation), 
and electroretinography parameters (scotopic rod response 
amplitude, maximal combined a-wave and b-wave ampli-
tudes, 30-Hz flicker amplitude, and 30-Hz flicker implicit 
time) at the most recent visit. Stability in visual acuity was 
defined as a visual acuity that was similar to the first visit 
(within one line on the Snellen chart). Improvement in visual 
acuity was defined as visual acuity that improved by at least 
two lines on the Snellen chart from the first visit. Stability 
of visual field was defined as the patient having the mean 
deviation and pattern standard deviation within the same 
category based on probability symbols on HVF printout. 
Visual field patterns were considered improved if scotomas 
in the field became more localized or less dense in the final 
visit than in the initial visit. Finally, electroretinography 
parameters were considered stable when they were within 
25% (minimum reported for stability) of the baseline values 
or better,23 respectively, from the first to the last visit.
As there were multiple parameters in the HVF and elec-
troretinography tests, stability or improvement in each test 
was defined as stability or improvement in .50% of the 
parameters of that test. Parameters included total deviation, 
pattern deviation, mean deviation, and pattern standard 
deviation in HVF; and scotopic rod response amplitude, 
maximal combined a-wave and b-wave amplitudes, 30-Hz 
flicker amplitude, and 30-Hz flicker implicit time in 
electroretinography. The test was determined to be inconclu-
sive when 50% of the parameters were worse and the other 
50% were stable or better.
statistical analysis
Statistical Package for the Social Sciences (SPSS) 16.0 (IBM 
Corp., Armonk, NY, USA) and MedCalc software 8.2.0.3 
(MedCalc®, Mariakerke, Belgium) were used for statistical 
analysis.
Results
There were six patients (12 eyes) who met all inclusion 
criteria. The median age at initial presentation was 49 years 
(range, 30–73). The median duration between onset of symptoms 
and initial consultation was 10.5 months (range, 2–44). The 
median duration of follow-up was 18 months (range, 8–49). 
Of the six patients, five (83.3%) were females. All patients 
were of a non-Hispanic Caucasian ethnicity. One patient 
had a previous diagnosis of systemic lupus erythematosus 
(patient 3), two patients had a previous diagnosis of birdshot 
retinochoroidopathy (patients 5 and 6), and one patient had 
a previous diagnosis of HLA-B27-positive panuveitis and 
vasculitis (patient 2). All patients’ family histories were 
negative for any systemic autoimmune, ocular autoimmune, 
and hereditary degenerative diseases.
At the initial visit, the mean LogMAR visual acuity was 
0.58±0.6 (20/70–20/80). The presenting symptoms included 
progressive decreased vision in four eyes of two patients, 
progressive decreased vision and visual field defects in 
four eyes of two patients, and only progressive visual field 
defects in two eyes of one patient. Two eyes of one patient 
with birdshot retinochoroidopathy were found, inciden-
tally, during regular monitoring with impressive changes 
in his visual field and electroretinography tests after almost 
4 years of being in remission off medications and without 
any intraocular inflammation. None of the eyes had active 
uveitis at the initial visit. Two of the six patients (four eyes) 
had abnormal funduscopy examinations; one of them (two 
eyes) showed disc pallor, arterial narrowing, and diffuse 
retinal and retinal pigment epithelium atrophy, whereas the 
other patient (two eyes) showed isolated generalized retinal 
and retinal pigment epithelium atrophy. All other patients 
had normal funduscopy exami nations bilaterally.
Fluorescein angiography did not reveal any abnormalities 
in any of the 12 eyes at the initial visit. ICG angiography 
was normal in eight eyes of four patients and was considered 
stable in patients who had previous diagnoses of birdshot 
retinochoroidopathy. Macular optical coherence tomography 
was obtained in four patients due to decreased visual acuity. 
Results of this testing showed decreased macular thickness 
with no macular edema or cystic changes in the macula in 
eight eyes of these four patients.
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All patients received immunomodulatory therapy. Four 
patients with underlying systemic or ocular autoimmune 
diseases were already on conventional immunomodulatory 
therapy, which included methotrexate, cyclosporine, myco-
phenolate mofetil, and adalimumab. All of these medications 
were stopped before using the AIR treatment protocol.
Rituximab was started in all the patients in the study. Oral 
cyclophosphamide was used in three patients. One patient 
received bortezomib in combination with rituximab as the 
initial therapy. Cyclophosphamide was replaced with bort-
ezomib in one patient because of documented leukopenia.
Treatment was prematurely stopped in two patients. 
One patient discontinued treatment due to intolerable side 
effects of the medications: rituximab, cyclophosphamide, and 
bortezomib. This patient experienced dermatitis (1 month 
after starting treatment), leukopenia (6 months after starting 
treatment), and peripheral neuropathy (2 months after 
starting treatment) with rituximab, cyclophosphamide, and 
bortezomib, respectively. The other patient discontinued 
treatment due to issues in insurance coverage (5 months after 
starting treatment). One patient, who was on rituximab and 
cyclophosphamide combination therapy, had to discontinue 
cyclophosphamide due to leukopenia (10 months after 
treatment), but was able to continue treatment with 
rituximab. The mean number of medications used to treat 
was 1.83 (range, 1–3). The average duration of treatment was 
14.1±5.07 months (range, 8–20). Table 1 shows the details 
of the treatment regimens in each patient.
Changes in vision, visual field patterns and parameters, 
and electroretinography parameters from the initial visit to 
the most recent visit are shown in Table 2 and Figure 1.
From the initial visit to the last visit recorded, visual acuity 
was found to be stable in eight (66.7%) eyes and decreased 
in four (33.3%) eyes. Visual field as a single test showed 
stability in six (50%) eyes, improvement in two (16.7%) eyes, 
and worsening in one (8.33%) eye. It was inconclusive in 
three eyes (25%). Figure 2 shows the improvement of mean 
deviation and stability of pattern standard deviation in one 
of the patients who responded to rituximab. Electroretinog-
raphy as a single test showed improvement in two (16.7%) 
eyes, worsening in four (33.3%) eyes, and stability in two 
(16.7%) eyes. In four (33.3%) eyes, electroretinography 
Table 1 non-paraneoplastic autoimmune retinopathy treatment regimens
Patient no/sex/age Treatment 
regimen
Duration of 
treatment (months)
Reason for treatment 
termination
Total duration of 
follow-up (months)
1/F/30 r + C + B 10 side effect to r, C, and B 17
2/F/47 r + C 18 Continued to the last visit 18
3/F/51 r 20 Continued to the last visit 20
4/F/73 r 11 insurance issue 49
5/M/54 r + C 18 side effect to C 18
6/F/40 r + B 8 Continued to the last visit 8
Abbreviations: B, bortezomib; C, cyclophosphamide; F, female; M, male; r, rituximab.
Table 2 Visual acuity, visual field parameters, and electroretinography parameters changes from the initial visit to the most recent visit 
in patients with non-paraneoplastic autoimmune retinopathy
Patient 
no/sex/
age/eye
Changea 
in V/A
Changea 
in HVF, 
MD
Changea 
in HVF, 
PSD
Changea 
in HVF, 
TD
Changea 
in HVF, 
PD
Changea 
in ERG, 
Sc b-wave
Changea 
in ERG, 
C a-wave
Changea 
in ERG, 
C b-wave
Changea 
in ERG, 
30-Hz Am
Changea 
in ERG, 
30-Hz Im
Negative 
wave-
forms
1/F/30/OD W s s i s W W i W s no
1/F/30/Os W s s s s W W W W W no
2/F/47/OD s s s s s W s i i s Yes
2/F/47/Os W s s s i i W i i W Yes
3/F/51/OD s W s W W s W s i i no
3/F/51/Os s s s W W i s s W s Yes
4/F/73/OD W s s s s W W W s s no
4/F/73/Os s s s s s W W W W i no
5/M/54/OD s i s i i i s s W i no
5/M/54/Os s s W s W i i s W i no
6/F/40/OD s s s W W s s s i i no
6/F/40/Os s i i i i s W W i i no
Note: aChange from the initial visit to the most recent visit.
Abbreviations: Am, amplitude; C, combined; ERG, electroretinography; F, female; HVF, Humphrey visual field; I, improved; Im, implicit time; M, male; MD, mean deviation; 
OD, right eye; Os, left eye; PD, pattern deviation; PsD, pattern standard deviation; s, stable; sc, scotopic; TD, total deviation; V/a, visual acuity; W, worse.
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Figure 1 Changes in vision, visual field parameters, and electroretinography parameters from the initial visit to the most recent visit in 12 eyes of six patients with 
non-paraneoplastic autoimmune retinopathy. (A) Changes in logMar visual acuity. (B) Mean deviation changes on Humphrey visual field. (C) Pattern standard deviation 
changes on Humphrey visual field. (D) Changes in scotopic rod response amplitude on ganzfeld electroretinography. (E) Changes in maximal response a-wave amplitude 
on ganzfeld electroretinography. (F) Changes in maximal response b-wave amplitude on ganzfeld electroretinography. (G) Changes in 30-Hz flicker amplitude on Ganzfeld 
electroretinography. (H) Changes in 30-Hz flicker implicit time on Ganzfeld electroretinography. The central box shows the 25th–75th percentile. The middle line 
represents the median. Vertical line extends from the minimum to the maximum. separate triangles show far out values (larger than the upper quartile plus three times the 
interquartile range). The solid line connects the median values.
Abbreviation: logMar, logarithm of the minimum angle of resolution.
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Figure 2 Changes in visual field parameters (improvement in the mean deviation and stability of pattern standard deviation) in one of the patients from the initial visit before 
starting rituximab (upper panel) to the last visit (lower panel).
Abbreviations: MD, mean deviation; PsD, pattern standard deviation.
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Figure 3 Changes in 30-Hz flicker electroretinography parameters (improvement in the Amp and IT) in one of the patients from the initial visit before starting rituximab 
(upper panel) to the last visit (lower panel).
Abbreviations: amp, amplitude; iT, implicit time.
showed stability/improvement (50% of electroretinography 
parameters were stable and the other 50% improved). 
Figure 3 shows improvement in 30-Hz flicker amplitude and 
implicit time on rituximab therapy based on the definition. 
In addition, one patient (16.7%), who exhibited bilateral (two 
eyes, 16.7%) negative waveforms on electroretinography at 
the initial visit, had documented improvement in one eye 
after treatment. One eye developed negative waveforms 
during the treatment. Table 3 shows changes in visual acuity, 
the HVF, and electroretinography as a single test modality 
from the initial visit to the last visit. Nine (75%) eyes of five 
(83.5%) patients showed stability or improvement in at least 
two test modalities, including visual acuity, visual field, and 
electroretinography.
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At the initial visit just before starting rituximab, all patients 
were positive for anti-retinal and anti-optic nerve antibod-
ies. The average number of anti-retinal antibody bands was 
2.83±2.31 (range, 1–7). All but one had at least one patho-
logically proven anti-retinal antibody band (mean, 1.5±1.04; 
range, 0–3). The average number of anti-optic nerve antibody 
bands was 2.33±1.03 (range, 1–3). The pathologically proven 
anti-optic nerve antibody band was found only in one patient. 
At the most recent visit, the average number of anti-retinal 
antibody bands was 2.33±1.96 (range, 1–6), and the average 
number of anti-optic nerve antibody bands was 1.66±1.36 
(range, 0–4). After treatment, the average number of patho-
logically proven anti-retinal autoantibodies bands was 1±0.89 
(range, 0–2); the average number of nonspecific anti-optic 
nerve antibodies was the same, although the number of 
bands decreased in five patients and increased in one patient. 
Interestingly, in three out of five patients with pathologically 
proven anti-retinal antibodies, at least one pathogenically 
proven band disappeared after treatment; however, one of 
these patients developed a new pathologically proven band. 
Table 4 describes pathologically proven and nonspecific 
anti-retinal and anti-optic nerve antibodies at the initial and 
most recent visits.
Discussion
On the basis of the presumed antibody-mediated mechanism2,5,6 
and our personal experience regarding the failures of con-
ventional immunomodulatory therapy (four patients in this 
cohort), we evaluated the efficacy of rituximab as a mono-
therapy or in combination with cyclophosphamide and/or 
bortezomib to preserve or improve visual functions in patients 
with non-paraneoplastic AIR. The rationale for this protocol 
was to eliminate the B cells, precursors of plasma cells that 
are responsible for making the autoantibodies against retinal 
cells. Oral cyclophosphamide and/or bortezomib were used 
in patients with severe disease.
Of the six patients, two patients (four eyes) were previously 
diagnosed with HLA-A29-positive birdshot retinochor-
oidopathy. These cases were in remission for a long time 
(.2 years). Neither of them had active intraocular inflam-
mation, especially vitreous cells and vitreous haze. They had 
subacute impressive visual field and visual acuity loss with 
normal fluorescein angiography and stable ICG angiography. 
These findings made us suspicious to AIR more than birdshot 
retinochoroidopathy relapse as AIR has previously been 
reported in cases with birdshot retinochoroidopathy.14 Both 
of these cases responded to rituximab infusions.
In our study, vision did not improve in any patient despite 
treatment; however, visual acuity was stable at the most recent 
visit in eight (66.7%) eyes. Ferreyra et al showed improved 
vision in three eyes of three patients out of 15 patients with 
non-paraneoplastic AIR who responded to immunosuppres-
sive therapy.6 Two patients in their study had cystoid macular 
edema that improved after treatment, which can explain the 
Table 3 Changes in visual acuity, hVF and electroretinography as 
single tests modalities from the initial visit to the most recent visit 
in patients with non-paraneoplastic autoimmune retinopathy
Patient no/
sex/age/eye
Changea 
in V/A
Changea 
in HVF
Changea 
in ERG
1/F/30/OD W s W
1/F/30/Os W s W
2/F/47/OD s s s/i
2/F/47/Os W s i
3/F/51/OD s W s/i
3/F/51/Os s s/W s
4/F/73/OD W s W
4/F/73/Os s s W
5/M/54/OD s i s/i
5/M/54/Os s s/W i
6/F/40/OD s s/W s
6/F/40/Os s i s/i
Note: aChange from the initial visit to the most recent visit.
Abbreviations: ERG, electroretinography; F, female; HVF, Humphrey visual field; 
i, improved; M, male; OD, right eye; Os, left eye; s, stable; s/i, stable/improved; 
s/W, stable/worse; V/a, visual acuity; W, worse.
Table 4 anti-retinal and anti-optic nerve autoantibody bands in non-paraneoplastic autoimmune retinopathy
Patient 
no/sex/
age
ARA bands 
(pathologic), 
first visit 
(kDa)
ARA bands 
(pathologic), 
last visit 
(kDa)
ARA bands 
(nonspecific), 
first visit 
(kDa)
ARA bands 
(nonspecific), 
last visit 
(kDa)
AOA bands 
(pathologic), 
first visit 
(kDa)
AOA bands 
(pathologic), 
last visit 
(kDa)
AOA bands 
(nonspecific), 
first visit 
(kDa)
AOA bands 
(nonspecific), 
last visit 
(kDa)
1/F/30 30, 46, 48 30, 45 31, 43, 62, 122 43, 60, 62, 112 n n 46, 62, 64 n
2/F/47 22 22 n n 22 22 n 131, 132, 135
3/F/51 40, 46 46 n n n n 46, 50, 62 36, 62
4/F/73 33–35 n n n n n 2, 104, 110 62
5/M/54 30, 46 30, 46 50, 72 72 n n 46, 72 72
6/F/40 n n 62, 76 62, 76 n n 32, 96, 136 135
Notes: 22, ara and aOa pathologic; 30, carbonic anhydrase ii; 33–35, Muller cell associated; 40, aldolase; 46, enolase; 48, arrestin.
Abbreviations: aOa, anti-optic nerve antibody; ara, anti-retinal antibody; F, female; M, male; n, negative.
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improvement in visual acuity.6 However, none of our patients 
tested with fluorescein angiography and optical coherence 
tomography had cystoid macular edema. Jampol and Fishman 
reevaluated and reanalyzed their data in patients with non-
paraneoplastic AIR without cystoid macular edema; they 
observed stability or improvement in 60% of studied eyes.24 
In our study, four patients had previous retinal, choroidal, 
and retinal vasculature problems, which might explain why 
their vision did not improve despite treatment. Moreover, 
three eyes of two patients with worsening of visual acuity 
were in the group in which the treatment was prematurely 
stopped due to side effects or insurance issues.
Most of the previous studies emphasized Goldman perim-
etry for peripheral visual changes; however, central and para-
central scotomas have been reported in patients with AIR.5 In 
addition, electroretinography shows peripheral retinal function 
accurately; therefore, we performed 24-2 FASTPAC or SITA-
FAST or SITA-SWAP strategy in our patients as these tests 
can also indicate optic nerve involvement. Different strategies 
were used based on the underlying problems in our patients; 
for example, we obtained SITA-SWAP data in patients with 
birdshot retinochoroidopathy.15 This does not interfere with 
the interpretation of the results, as we compared the status of 
patients at their most recent visit with their own baseline mea-
surements. In our study, visual field improved in two eyes of 
two patients. Our results are not as favorable as those found by 
Ferreyra et al using Goldmann perimetry;6 however, our criteria 
for visual field improvement were very strict. In addition, we 
used the HVF test, which has more parameters than Goldman 
perimetry, the method used by Ferreyra et al. Our findings were 
consistent with Jampol and Fishman reanalysis of Ferreyra et al’s 
results, in that they found no change in Goldman perimetry 
with IV-4-e target in half of the patients.24 These findings 
make our results superior to that study when taking into 
account our strict criteria. Moreover, all of our patients had 
autoimmune-related retinopathy and optic neuropathy syn-
drome, which might make the prognosis poorer than that of 
isolated AIR.
The major advantage of this study, as opposed to previous 
studies on this disorder, was the comprehensive evaluation 
of electroretinography parameters and their changes from 
the initial to the final visit while considering inter-test 
variability.6,11,12,20 The majority of parameters were stable or 
improved in eight eyes (66.7%). The four eyes with wors-
ening of the majority of the parameters on electroretinog-
raphy belonged to two patients in whom the treatment was 
stopped prematurely due to insurance issues or side effects. 
Only limited case reports and small case series reported 
electrophysiological data with no pathognomonic findings; in 
addition, most of our patients were asymptomatic in the most 
recent visit. As such, the importance of this finding is not 
completely clear. The largest cohort of non-paraneoplastic 
AIR patients, performed by Ferreyra et al, did not include 
electroretinography parameters in the improvement criteria 
in all of their patients.6
We divided anti-retinal and anti-optic nerve antibodies 
into pathologically proven and nonspecific groups based 
on the previous studies.2,5,14 The importance of nonspecific 
anti-retinal and anti-optic nerve antibodies is unclear. Half 
of our patients showed elimination of at least one pathologi-
cally proven anti-retinal antibody band (Table 4). This can 
indicate the efficacy of treatment; however, due to the rarity 
of the disease, lack of standardization of these tests, and low 
antibody-specific concordance rate, this is still an area of 
debate.8,25 Although antibody titers may be more valuable than 
the bands themselves in reporting efficacy of treatment, titers 
were not available in antibody reports from the laboratory.
Despite all of these controversies, stability or improve-
ment of two or more tests in nine (75%) eyes of five (83.5%) 
patients along with the reduction of pathologically proven 
antibody bands (50%) can be considered a success in the 
treatment of this disease, which historically has had a poor 
prognosis. This becomes more significant if we consider that 
all three eyes with worsening of at least two test modalities 
were in the group in which the treatment was prematurely 
stopped. However, due to ongoing underlying autoimmune 
processes and the unpredictability of this rare disorder, the 
duration of treatment and the final prognoses of these patients 
are still unclear.
Our study was limited by its retrospective nature and 
small sample size. Not having optical coherence tomography 
data for all patients was another limitation of our study. We 
were also dependent on a commercially available laboratory 
for anti-retina and anti-optic nerve antibodies, and they did 
not include the antibodies’ titers in their reports. Moreover, 
the patient population in our tertiary referral center is skewed 
toward patients with very severe intraocular disease. Thus, it 
is difficult to predict from our data, the outcomes of treatment 
in patients with a milder disease course. Notwithstanding 
these limitations, this article describes the only cohort to date 
of patients with non-paraneoplastic AIR who were treated 
with rituximab as a monotherapy or in combination with 
cyclophosphamide and/or bortezomib with a comprehensive 
analysis of the static visual field, electroretinography, and 
anti-retinal and anti-optic nerve antibodies.
Overall, stability of vision, visual field, and electroretin-
ography parameters were observed in a high number of eyes 
(75%) who were treated with rituximab as monotherapy (one 
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patient) or combination therapy (four patients). However, a 
prospective multi-center study with a large population and 
longer follow-up would help us to standardize the use of 
visual field, electroretinography parameters, and evaluation 
of anti-retinal and anti-optic nerve antibody bands and titers 
so that criteria can be established for a proper response to 
treatment with rituximab, alone or in combination therapy.
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